Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.
Use of oral capsules in the delivery of faecal microbiota transplantation (FMT) appears to be equally effective as colonoscopy in terms of preventing recurrent Clostridium difficile infection (RCDI) over 12 weeks, according to the results of a trial.
Elderly patients with Clostridium difficile (C. difficile) infection who were given extended-pulsed fidaxomicin were more likely to have sustained clinical cure a month after treatment than those on standard-dose vancomycin, results of the phase 3b/4 EXTEND* trial show.
The risk of Clostridium difficile infection (CDI) in hospitalized patients may be halved by a strategy of administering probiotics within 2 days of antibiotic initiation, according to the results of a systematic review.
Bezlotoxumab, a human monoclonal antibody against Clostridium difficile (C. difficile) toxin B, appears to reduce the risk of recurrent C. difficile infection, according to findings from the MODIFY I* and MODIFY II** trials.
Foecal microbiota transplantation (FMT) done through the lower gastrointestinal (LGI) delivery route appears to be the most effective way for the prevention of recurrence/relapse of Clostridium difficile infection (CDI), suggests a study.
Transfer of sterile filtrates, rather than faecal microbiota, from donor stool may be enough to restore normal stool habits and eliminate symptoms in patients with Clostridium difficile infection (CDI), according to a study.
New drug applications approved by US FDA as of 16 - 31 October 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The serum pepsinogen test—which is relatively
simple, inexpensive, sensitive and specific—is a potentially viable method for
the screening and detection of Kazakh early gastric cancer, a new study claims.
Helicobacter pylori (H. pylori) infection is associated with conditions such as gastritis, peptic ulcer, gastric cancer, and certain types of lymphoma. A common presenting complaint among all these H. pylori-related illnesses is dyspepsia. Dr Desmond Wai from the Desmond Wai Liver and Gastrointestinal Diseases Centre, Mount Elizabeth Novena Specialist Centre, Singapore, speaks on the important role general practitioners (GPs) play in recognizing, diagnosing, and treating H. pylori.
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.